How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking 'cheap'.

| More on:
Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have gone backwards over the past year.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock closed up 0.99% on Monday trading for $244.29.

Despite that welcome boost, shares remain down 10.61% in 12 months, underperforming the 5.56% gains posted by the ASX 200 over this same time.

Although it's worth noting that those losses will have been modestly mitigated by CSL's dividends. The stock trades on an unfranked trailing dividend yield of 1.7%.

While CSL shares have been under selling pressure since last August, United States President Donald Trump's indication that imported medicines may get hit with tariffs hasn't done shareholders any favours.

But, according to Catapult Wealth's Dylan Evans, the market's reaction to those as-yet undeclared tariffs could make now an opportune time to buy stock in CSL (courtesy of The Bull).

Why CSL shares are a buy

"The share price of this biotechnology giant has been trending down since mid-2024," said Evans, who has a buy recommendation on CSL shares.

Commenting on Trump's tariff warnings, he said, "Threats from the Trump Administration to extend tariffs to imported pharmaceuticals would possibly have a negative impact on CSL, given it generates around half its revenue in the US."

But that isn't dissuading him from buying the biotech stock.

"Despite these risks, we believe CSL represents good value," Evans said. "It remains a high quality company, delivering double digit earnings growth. It looks cheap compared to global peers."

And with the market having already discounted CSL amid expectations of those tariffs, Evans noted, "The impact of US tariffs is factored into the share price, so, in our view, there's upside potential if they are withdrawn, or lower than anticipated."

Also bullish on the ASX 200 biotech stock

Tyndall Asset Management's Tim Johnston also has a bullish outlook for CSL shares (courtesy of The Australian Financial Review).

Atop headwinds from potential US tariffs on pharmaceuticals, CSL has also come under pressure following the confirmation of Robert F Kennedy junior, a vaccine sceptic, as US health and human services secretary.

At the company's half-year results (H1 FY 2025), CSL already reported a 9% decline in revenue at Seqirus, its vaccine division. That was driven by low immunisation rates, especially in the US.

But Johnston doesn't believe these headwinds will persist for CSL shares.

"Common sense will prevail, science will win out," he said of the US vaccination rates.

"And CSL at 21 times earnings for a stock that's probably going to deliver low double-digit earnings growth for the foreseeable future is as cheap as I have seen it," Johnston said.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »